S Intidhar Labidi-Galy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2789488/publications.pdf

Version: 2024-02-01

41	3,033	331670 21	233421 45
papers	citations	h-index	g-index

47	47	47	5924
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas. Cancer Research, 2009, 69, 5383-5391.	0.9	610
2	High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications, 2017, 8, 1093.	12.8	515
3	Impaired IFN-Î± Production by Plasmacytoid Dendritic Cells Favors Regulatory T-cell Expansion That May Contribute to Breast Cancer Progression. Cancer Research, 2012, 72, 5188-5197.	0.9	285
4	Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer. Cancer Research, 2011, 71, 5423-5434.	0.9	200
5	Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell, 2021, 39, 1091-1098.e2.	16.8	199
6	Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecologic Oncology, 2014, 132, 542-550.	1.4	128
7	Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. OncoImmunology, 2012, 1, 380-382.	4.6	114
8	Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. OncoImmunology, 2012, 1, 432-440.	4.6	102
9	Breast cancerâ€derived transforming growth factorâ€Î²2 and tumor necrosis factorâ€Î± compromise interferonâ€Î± production by tumorâ€associated plasmacytoid dendritic cells. International Journal of Cancer, 2013, 133, 771-778.	5.1	80
10	Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Seminars in Cancer Biology, 2021, 77, 127-143.	9.6	59
11	Bevacizumab and Paclitaxel for Breast Cancer Patients with Central Nervous System Metastases: A Case Series. Clinical Breast Cancer, 2009, 9, 118-121.	2.4	58
12	Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. Scientific Reports, 2020, 10, 7073.	3.3	57
13	Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene, 2015, 34, 373-383.	5.9	42
14	Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response. Critical Reviews in Oncology/Hematology, 2016, 101, 50-59.	4.4	40
15	Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer. Clinical Cancer Research, 2018, 24, 326-333.	7.0	40
16	Inflammatory breast cancer in Tunisia in the era of multimodality therapy. Annals of Oncology, 2008, 19, 473-480.	1.2	36
17	Endometriosis-associated ovarian carcinomas: insights into pathogenesis, diagnostics, and therapeutic targetsâ€”a narrative review. Annals of Translational Medicine, 2020, 8, 1712-1712.	1.7	36
18	Serum cytokines in follicular lymphoma. Correlation of TGF-Î²2 and VEGF with survival. Annals of Hematology, 2010, 89, 25-33.	1.8	34

#	Article	IF	Citations
19	Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin. BMC Cancer, 2008, 8, 28.	2.6	32
20	CD4 lymphopenia to identify end-of-life metastatic cancer patients. European Journal of Cancer, 2013, 49, 1080-1089.	2.8	31
21	PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. Cancer Treatment Reviews, 2021, 99, 102255.	7.7	25
22	Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?. Cancer Treatment Reviews, 2021, 97, 102204.	7.7	24
23	Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. Journal of Pathology, 2018, 246, 459-469.	4.5	23
24	Clinical Development of Anti-mitotic Drugs in Cancer. Advances in Experimental Medicine and Biology, 2017, 1002, 125-152.	1.6	22
25	Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. Bulletin Du Cancer, 2010, 97, E23-E32.	1.6	21
26	Imatinib mesilate for the treatment of gastrointestinal stromal tumour. Expert Opinion on Pharmacotherapy, 2008, 9, 1211-1222.	1.8	19
27	Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers. Gynecologic Oncology, 2019, 155, 262-269.	1.4	19
28	Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. European Journal of Cancer, 2021, 152, 68-77.	2.8	18
29	Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms. Gynecologic Oncology, 2014, 132, 328-333.	1.4	17
30	Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. Breast, 2007, 16, 352-358.	2.2	15
31	BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients. Breast Cancer Research and Treatment, 2019, 174, 775-783.	2.5	15
32	Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis. Gynecologic Oncology, 2020, 156, 377-386.	1.4	14
33	Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994â€“1998 and 2003â€“2006. Breast Cancer Research and Treatment, 2011, 128, 187-195.	2.5	10
34	Therapeutic pipeline for soft-tissue sarcoma. Expert Opinion on Pharmacotherapy, 2011, 12, 2479-2491.	1.8	9
35	Medullary thyroid cancer treated by capecitabine. Anti-Cancer Drugs, 2007, 18, 831-834.	1.4	8
36	Hepatic veno-occlusive disease after tandem autologous stem cell transplantation conditioned by melphalan. International Journal of Hematology, 2008, 88, 291-293.	1.6	8

#	Article	IF	Citations
37	Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation. Gynecologic Oncology Reports, 2020, 33, 100600.	0.6	8
38	Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study. Bulletin Du Cancer, 2011, 98, E80-E89.	1.6	6
39	First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer. Bulletin Du Cancer, 2012, 99, E18-E25.	1.6	3
40	Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis.. Journal of Clinical Oncology, 2020, 38, 1087-1087.	1.6	2
41	Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.. Journal of Clinical Oncology, 2022, 40, 5571-5571.	1.6	2